Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1329486 | 0.89 | RECQL (0.43) | HPGDUSP30GPR119RECQLJAK2 | |
| SCHEMBL16584528 | 0.87 | HPGD (0.44) | HPGDUSP30GPR119RECQLJAK2 | |
| SCHEMBL16584530 | 0.87 | HPGD (0.44) | HPGDUSP30GPR119RECQLJAK2 | |
| SCHEMBL20358501 | 0.87 | NR1H2 (0.42) | HPGDUSP30GPR119RECQLEPHX1 | |
| SCHEMBL20360129 | 0.87 | NR1H2 (0.42) | HPGDUSP30GPR119RECQLEPHX1 | |
| SCHEMBL20358500 | 0.87 | NR1H2 (0.42) | HPGDUSP30GPR119RECQLEPHX1 | |
| SCHEMBL17920094 | 0.87 | USP30 (0.40) | HPGDUSP30GPR119RECQLJAK2 | |
| SCHEMBL17920093 | 0.86 | USP30 (0.40) | HPGDUSP30GPR119RECQLJAK2 | |
| SCHEMBL17913842 | 0.85 | JAK2 (0.40) | HPGDUSP30GPR119RECQLJAK2 | |
| SCHEMBL586312 | 0.83 | HPGD (0.54) | HPGDUSP30GPR119RECQLJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11319321-B2 | [1,2,4]triazolo[1,5-a]pyrimidine compounds as PDE2 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2022-05-03 | — | — | US | disclosed |
| CN-107406414-B | (piperidin-3-yl) (naphthalen-2-yl) methanone derivatives as inhibitors of histone demethylase KDM2B for the treatment of cancer | 基因泰克公司 | 2022-04-19 | — | — | CN | disclosed |
| US-11053248-B2 | [1,2,4]triazolo[1,5-a]pyrimidine compounds as PDE2 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-07-06 | — | — | US | disclosed |
| US-10947239-B2 | [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compound | JANSSEN PHARMACEUTICA NV (BE) | 2021-03-16 | — | — | US | disclosed |
| US-10947242-B2 | [1,2,4]triazolo[1,5and#8208;A]pyrimidine compounds as PDE2 inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2021-03-16 | — | — | US | disclosed |
| EP-3535267-B1 | [1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AS PDE2 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-30 | — | — | EP | disclosed |
| EP-3535269-B1 | [1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS PDE2 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-09 | — | — | EP | disclosed |
| US-20200157092-A1 | [1,2,4]-TRIAZOLO [1,5-A]-PYRIMIDINYL DERIVATIVES SUBSTITUTED WITH PIPERIDINE, MORPHOLINE OR PIPERAZINE AS OGA INHIBITORS | Janssen Pharmaceutlca NV (BE) | 2020-05-21 | — | — | US | disclosed |
| US-20200055858-A1 | [1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS PDE2 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-02-20 | — | — | US | disclosed |
| US-20200048260-A1 | [1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS PDE2 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-02-13 | — | — | US | disclosed |
| US-20160102102-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-04-14 | — | — | US | disclosed |
| US-20160102102-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-04-14 | — | — | US | disclosed |
| US-9216999-B2 | Substituted pyrrolo[2,3-h][1,6]naphthyridines and compositions thereof as JAK inhibitors | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-12-22 | — | — | US | disclosed |
| US-9216999-B2 | Substituted pyrrolo[2,3-h][1,6]naphthyridines and compositions thereof as JAK inhibitors | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-12-22 | — | — | US | disclosed |
| US-9216999-B2 | Substituted pyrrolo[2,3-h][1,6]naphthyridines and compositions thereof as JAK inhibitors | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-12-22 | — | — | US | disclosed |
| US-20140200344-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2014-07-17 | — | — | US | disclosed |
| US-20140200344-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2014-07-17 | — | — | US | disclosed |
| EP-2742049-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | Nissan Chemical Industries, Ltd. (JP) | 2014-06-18 | — | — | EP | disclosed |
| WO-2013024895-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-02-21 | — | — | WO | disclosed |
| WO-2013024895-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055858-A1 | [1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS PDE2 INHIBITORS | PDE2A, PDE12, PDE5A | HPGD 388/4885USP30 2573/4885GPR119 1803/4885 |
| US-20160102102-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | JAK2, JAK1, JAK3 | HPGD 3560/4885USP30 2453/4885GPR119 2712/4885 |
| US-20200157092-A1 | [1,2,4]-TRIAZOLO [1,5-A]-PYRIMIDINYL DERIVATIVES SUBSTITUTED WITH PIPERIDINE, MORPHOLINE OR PIPERAZINE AS OGA INHIBITORS | OGA, PSEN1, PSEN2 | HPGD 3346/4885USP30 928/4885GPR119 2188/4885 |
| US-20200048260-A1 | [1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS PDE2 INHIBITORS | PDE2A, PDE12, PDE5A | HPGD 388/4885USP30 2573/4885GPR119 1803/4885 |
| US-10947239-B2 | [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compound | PDE2A, PDE5A, PDE12 | HPGD 512/4885USP30 2605/4885GPR119 1499/4885 |
| US-20140200344-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | JAK2, JAK1, JAK3 | HPGD 2010/4885USP30 2457/4885GPR119 2875/4885 |
| US-11319321-B2 | [1,2,4]triazolo[1,5-a]pyrimidine compounds as PDE2 inhibitors | PDE2A, PDE12, PDE5A | HPGD 388/4885USP30 2573/4885GPR119 1803/4885 |
| US-11053248-B2 | [1,2,4]triazolo[1,5-a]pyrimidine compounds as PDE2 inhibitors | PDE2A, PDE12, PDE5A | HPGD 388/4885USP30 2573/4885GPR119 1803/4885 |
| US-10947242-B2 | [1,2,4]triazolo[1,5and#8208;A]pyrimidine compounds as PDE2 inhibitors | PDE2A, PDE12, PDE5A | HPGD 198/4885USP30 2656/4885GPR119 1852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.